Secukinumab treated patients in the Australian clinical practice setting: HOPE study investigating the quality of life in patients with severe chronic plaque psoriasis after treatment

被引：0
|
作者：
Foley, P. [1 ]
Walsh, M. [2 ]
Mate, E. [2 ]
机构：
[1] Skin & Canc Fdn Inc, Carlton, Vic, Australia
[2] Novartis Pharmaceut Australia Pty Ltd, Macquarie Pk, NSW, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [21] Quality of life in plaque psoriasis patients treated with biologics: A systematic review
    Prado, Giselle
    Nichols, Anna
    Florez-White, Mercedes
    Kerdel, Francisco
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB236 - AB236
  • [22] Clinical outcomes and quality of life in a cross-sectional study of patients with moderate-to-severe psoriasis treated with bimekizumab in routine clinical practice
    Wicker, Gemma
    Tredwell, Amanda
    Topliffe, Joanne
    Smith, Maureen
    Vistenia, Jason
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I66 - I66
  • [23] ADHERENCE AND PERSISTENCE AMONG US PATIENTS INITIATING SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
    Feldman, S. R.
    Zhao, Y.
    Gray, S.
    Montejano, L. B.
    Lin, F.
    Herrera, V
    VALUE IN HEALTH, 2017, 20 (05) : A159 - A159
  • [24] Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
    Jo Lambert
    Jes Birger Hansen
    Anne Sohrt
    Luis Puig
    Dermatology and Therapy, 2021, 11 : 1265 - 1275
  • [25] Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real-world practice
    Zhou, Jian
    Yuan, Yuan
    Liu, Yanhua
    Chu, Mengyang
    Liu, Huan
    Liu, Qian
    Wang, Rui
    Shao, Shuai
    Wang, Gang
    Yu, Chen
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (01)
  • [26] Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
    Lambert, Jo
    Hansen, Jes Birger
    Sohrt, Anne
    Puig, Luis
    DERMATOLOGY AND THERAPY, 2021, 11 (04) : 1265 - 1275
  • [27] Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study
    Zhao, Yan
    Cai, Lin
    Liu, Xiao-Yang
    Zhang, Heng
    Zhang, Jian-Zhong
    CHINESE MEDICAL JOURNAL, 2021, 134 (11) : 1324 - 1328
  • [28] Secukinumab treated patients in the PURE registry (patients with moderate to severe chronic plaque psoriasis in Latin America and Canada): 18 month follow up data
    Mate, E.
    Papp, K.
    Gooderham, M.
    Lynde, C.
    Langley, R.
    Alam, M.
    Beecker, J.
    Rampakakis, E.
    Boucher, A.
    Hussein, S.
    Rihakova, L.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 60 - 60
  • [29] Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting
    Ogut, Neslihan Demirel
    Yildirim, Sema Koc
    Erbagci, Ece
    Hapa, Fatma Asli
    JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (11) : 6215 - 6224
  • [30] Assess the impact of pruritus on quality of life of patients with chronic plaque psoriasis
    Bhatia, Kailash
    Syed, Amin
    Kataria, Rajesh
    Dayal, Satgur
    Namdeo, Chaitanya
    Bhatia, Jushya
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB48 - AB48
12345